This article originally appeared on VICE US.
There was a time when waking up with a scratchy throat or a dry cough didnt elicit such a sense of dread, but Covid-19 has made us all hyper-aware of its symptoms. Many people have been left wondering if they are asymptomatic carriers of the disease, or if a slight cold they may have recently experienced was actually something more menacing.
These fears are not unfounded: More than a million patients around the world have confirmed cases of coronavirus, but the real number of infections is far higherthough nobody yet knows by how much.
Thats why medical professionals are rushing to develop tests for antibodies that might reveal if a patient ever contracted Covid-19, regardless of whether they experienced symptoms. These tests may even be able to determine individual immunities to the virus, which has led to speculation that some people could reenter the workforce or resume normal activities if they have the right antibodies.
While this proposed solution may provide a sense of hope, it is far from a certain outcome at this point in time. Theres no clear consensus about the immunological response to Covid-19, and murky ethical problems undergird the idea of lifting restrictions on some populations, while isolating others, especially based on unsettled science.
Heres what you need to know about these tests, their development, and their potential to influence the global Covid-19 response.
Antibody tests, also known as serological tests, differ from the diagnostic swab tests that have been in high demand since the pandemic gained momentum.
Swab tests, or PCR tests, are designed to directly detect the virus by searching for its RNA, which is a genetic signature of its presence. These tests require collection of mucus samples from patients, typically sourced from deep within the nasal cavity, which are then sent to a laboratory to be examined. If the results come back positive, the patient is considered an active carrier of Covid-19 who could potentially infect other people.
Antibody tests, in contrast, dont look for the virus itself, but rather our immunological response to it. When our bodies are invaded by antigens such as the coronavirus, our immune systems react by creating a type of blood protein called an antibody. Antibodies flow through the blood, attacking the alien antigens by binding to them, which can neutralize the spread of infection. Many known antibodies can be detected with a quick blood test.
The idea is that you have volunteers who have recovered from infection, and you look to see what antibodies theyre expressing and test that against samples of the virus, basically, to see what are the circulating antibodies that recognize your virus, said Ruth Collins, professor of molecular medicine at Cornell University College of Veterinary Medicine, in a call.
It can take several weeks for the immune system to develop antibodies to fight a virus, which means positive serological tests may not indicate an active infection. Instead, the presence of coronavirus antibodies demonstrates if a patient ever had Covid-19, whether or not they experienced symptoms.
While it is common for an exposed person to develop immunity to other known viruses, it is important to emphasize that nobody knows yet whether the presence of Covid-19 antibodies indicates that a patient has either temporary or permanent immunity to the infection.
We dont know yet exactly how peoples immune systems respond to the infection, so wed have to find something that would mark everybodys response to the virusthe universal human response to the virusand to make sure that it was specific to this virus, Collins said.
These things are doable, she added, they just take a long time to work out.
Short answer: We have no idea.
Countless teams of scientists around the world are developing serological tests to detect antibodies related to Covid-19, including researchers at the Centers for Disease Control (CDC). Last Thursday, the US Food and Drug Administration approved the first test for antibodies test for Covid-19, though it is intended as a diagnostic test for active infections.
Last week, a team of scientists at Stanford University conducted finger-prick blood tests on 3,200 volunteers to help refine their antibody test. Likewise, in Italy, an entire town of 3,000 people that already received swab tests is now in the process of providing blood samples to follow-up on the diagnostic data with antibody studies.
Regardless, there have also been setbacks with the roughly 100 test kits for these antibodies that are already in development. None of these tests are close to reaching the high bar required for public distribution.
"Theres so much we really dont know"
Youd have to have a very high specificity and sensitivity, so you would be able to pick up even small amounts of those antibodies or the evidence of infection in people's blood, Collins said. Without that, you could well have people that have been infected without knowing about it, she continued, or people who might think they were still naive, immunologically, when in fact they werent.
In other words, antibody tests not only need to be good enough to yield reliable positive results, they also need to clearly show who does not have Covid-19 antibodies. Finding the right balance requires making sure that antibodies linked to viruses that arent Covid-19 do not produce false positives, and ensuring that the antibodies that are specifically linked to this particular coronavirus cannot evade detection.
Its hard to predict how long this process will take, given that so many teams are actively working on it, but its probably optimistic to expect they will take weeks or even months to be widely available to the public.
This timeline might be further delayed by new revelations about Covid-19. For instance, its possible that some carriers may never develop symptoms, but could still remain infectious to others for months.
Theres not even a consensus that everybody will completely clear the virus from their system, Collins noted. Some people may be asymptomatic shedders for a while. Theres so much we really dont know.
The phrase immunity passport has been floated by the government of the United Kingdom, and others, as a potential way to allow people with immunity to Covid-19 to return to regular work and travel routines.
Assuming that widespread serological testing is achievable, the idea is that people with antibodies linked to Covid-19 would be cleared of social distancing measures because they are theoretically immune to the virus and cannot actively spread it. This would bring back some normalcy for some of the population, and it would also enable scientists to better estimate the total number of Covid-19 cases, as opposed to confirmed cases involving patients who were sick enough to receive a swab test.
On the flip side, antibody tests for this purpose raise concerns about privacy rights and employment inequities, given that authorities would be using medical information to judge whether patients can return to work and normal life.
In the United States, the Americans with Disabilities Act (ADA) and the Genetic Information Act (GINA) prevent employers from discriminating on the basis of disability or genetic information. But discrimination for health reasons remains legal in many contexts in the United States, according to Jessica Roberts, director of the Health Law and Policy Institute at the University of Houston Law Center.
"We can go some way towards knowing who has been infected, but the idea of it being used as employment criteria is somewhat dystopian
Both laws would likely permit employers to screen employees for antibodies, Roberts said in an email. She noted that GINA only applies to genetic test results and family medical history, which are not likely to apply to antibody tests, which do not look for individual genetic information.
Moreover, the ADA actually allows employers to discriminate if employing a person with a disability could threaten the safety of the workplace, Roberts added. Assuming that ADA protection applies to people with Covid-19 (which a court would have to ask whether having Covid-19 constitutes a legally recognized disability), the employer could still prohibit an employee from coming to work if the employer could show that the employee would pose a significant risk.
The notion of planning a staggered reopening of society, in which restrictions are lifted on people judged immune to Covid-19, is inherently risky on both an epidemiological and ethical level.
While it may be soothing to daydream about receiving an immunity passport that allows you to return to your "normal" life, it is probably better to invest your energy in adapting to the restrictions, following health guidelines until more information is available, and working towards a better "normal" in whatever way you can.
It sounds good because it gives us what we want, which is definitive answers, Collins said.
But we dont know enough to be able to provide those definitive answers. We can go some way towards knowing who has been infected, but the idea of it being used as employment criteria is somewhat dystopian.
View original post here:
What Are Antibody Tests, and Can They Prove Coronavirus Immunity? - VICE
- Clemson professor Trudy Mackay elected to the National Academy of Medicine - Clemson News - October 22nd, 2024
- Research sheds new light on the behavior of KRAS gene in pancreatic and colorectal cancer - News-Medical.Net - October 22nd, 2024
- Pushing the boundaries of rare disease diagnostics with the help of the first Undiagnosed Hackathon - Nature.com - October 22nd, 2024
- Tailored Genetic Medicine: AAV Gene Therapy and mRNA Vaccines Redefine Healthcare's Future - Intelligent Living - October 22nd, 2024
- The Genetic Link to Parkinson's Disease - Hopkins Medicine - August 27th, 2022
- Epic Bio makes gene therapies by editing the epigenome - Labiotech.eu - August 27th, 2022
- Ovid turns to gene therapy startup to restock drug pipeline - BioPharma Dive - August 27th, 2022
- Whole-exome analysis of 177 pediatric patients with undiagnosed diseases | Scientific Reports - Nature.com - August 27th, 2022
- First Gene Therapy for Adults with Severe Hemophilia A, BioMarin's ROCTAVIAN (valoctocogene roxaparvovec), Approved by European Commission (EC) -... - August 27th, 2022
- Arbor Biotechnologies Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in Rare Liver Diseases - BioSpace - August 27th, 2022
- ElevateBio Partners with the California Institute for Regenerative Medicine to Accelerate the Development of Regenerative Medicines - Business Wire - August 27th, 2022
- ElevateBio and the University of Pittsburgh Announce Creation of Pitt BioForge BioManufacturing Center at Hazelwood Green to Accelerate Cell and Gene... - August 27th, 2022
- Genetic variants cause different reactions to psychedelic therapy - The Well : The Well - The Well - August 27th, 2022
- Personalized Medicine for Prostate Cancer: What It Is and How It Works - Healthline - August 27th, 2022
- Four radical new fertility treatments just a few years away from clinics - The Guardian - August 27th, 2022
- Why are Rats Used in Medical Research? - MedicalResearch.com - August 27th, 2022
- The Columns Stepping Stones in STEM Washington and Lee University - The Columns - August 27th, 2022
- Study points to new approach to clearing toxic waste from brain Washington University School of Medicine in St. Louis - Washington University School... - August 27th, 2022
- ALS Gene Therapy SynCav1 Found to Extend Survival in Mouse Model |... - ALS News Today - August 27th, 2022
- A New Kind of Chemo | The UCSB Current - The UCSB Current - August 27th, 2022
- Unraveling the mystery of who gets lung cancer and why - Genetic Literacy Project - June 16th, 2022
- How diet and the microbiome affect colorectal cancer - EurekAlert - June 16th, 2022
- Akouos Presents Nonclinical Data Supporting the Planned Clinical Development of AK-OTOF and Strategies for Regulated Gene Expression in the Inner Ear... - May 20th, 2022
- Money on the Move: SwanBio, Remix, Locus, Mirvie and More - BioSpace - May 20th, 2022
- DiNAQOR Opens DiNAMIQS Subsidiary to Partner with Gene Therapy Companies Bringing New Treatments to Patients - PR Newswire - May 20th, 2022
- Brain tumor growth may be halted with breast cancer drug - Medical News Today - May 20th, 2022
- LogicBio Therapeutics to Present at HC Wainwright Global Investment Conference - PR Newswire - May 20th, 2022
- Genascence Announces Data From Phase 1 Clinical Trial on GNSC-001, Company's Lead Program in Osteoarthritis, Presented at American Society of Gene... - May 20th, 2022
- Encoded Therapeutics Presents Nonclinical Data Showing Genomic Medicine Platform Yields Selective Expression to Optimize Gene Therapy Performance at... - May 20th, 2022
- California, Other States to Cover Rapid WGS of Newborns Under Medicaid, but Questions of Access Loom - GenomeWeb - May 20th, 2022
- Researchers Identify Role of 'Sonic the Hedgehog' Gene in Bone Repair - BioSpace - May 20th, 2022
- Targeting the Uneven Burden of Kidney Disease on Black Americans - The New York Times - May 20th, 2022
- ASC Therapeutics, U Mass Medical School, and the Clinic for Special Children Announce Podium Presentation of Safety and Efficacy in Murine and Bovine... - May 20th, 2022
- UC Davis Looks to Expand Genetic Breast Cancer Risk Education, Outreach for Hispanic Women - Precision Oncology News - May 20th, 2022
- Fly Researchers Find Another Layer to the Code of Life - Duke Today - May 20th, 2022
- CANbridge-UMass Chan Medical School Gene Therapy Research Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting - Business... - May 20th, 2022
- Omicron BA.4 and BA.5: What to know about the new variants - Medical News Today - May 20th, 2022
- Krystal Biotech to Present Additional Data on B-VEC from the GEM-3 Phase 3 Study at the Society for Investigative Dermatology Annual Meeting -... - May 20th, 2022
- FDA approves Lilly's Mounjaro (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2... - May 20th, 2022
- Elucidating the developmental origin of life-sustaining adrenal glands | Penn Today - Penn Today - May 20th, 2022
- 5 questions facing gene therapy in 2022 - BioPharma Dive - January 17th, 2022
- In a First, Man Receives a Heart From a Genetically Altered Pig - The New York Times - January 17th, 2022
- Antibodies, Easy Single-Cell, Genomics for All: Notes from the JP Morgan Healthcare Conference - Bio-IT World - January 17th, 2022
- Using genetics to conserve wildlife - Pursuit - January 17th, 2022
- Genetics of sudden unexplained death in children - National Institutes of Health - January 17th, 2022
- Amicus Therapeutics Reports Preliminary 2021 Revenue and Provides 2022 Strategic Outlook and Revenue Guidance - Yahoo Finance - January 17th, 2022
- Maze Therapeutics Announces $190 Million Financing to Support the Advancement of Nine Precision Medicine Programs and Compass Platform for Genetically... - January 17th, 2022
- How The mRNA Vaccines Were Made: Halting Progress and Happy Accidents - The New York Times - January 17th, 2022
- Press Registration Is Now Open for the 2022 ACMG Annual Clinical Genetics Meeting - PRNewswire - January 17th, 2022
- A Novel Mutation in the TRPM4 Gene | RRCC - Dove Medical Press - January 17th, 2022
- Biomarkers and Candidate Therapeutic Drugs in Heart Failure | IJGM - Dove Medical Press - January 17th, 2022
- Genetic counseling program helps patients take control of their health - Medical University of South Carolina - June 24th, 2021
- One-year-old baby in UAE receives imported genetic medicine to treat rare disease - Gulf News - June 24th, 2021
- Black and non-Hispanic White Women Found to Have No Differences in Genetic Risk for Breast Cancer - Cancer Network - June 24th, 2021
- What's in your genes | The Crusader Newspaper Group - The Chicago Cusader - June 24th, 2021
- Immusoft Announces Formation of Scientific Advisory Board - Business Wire - June 24th, 2021
- Arrowhead Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver Congress - Business... - June 24th, 2021
- Pacific Biosciences and Rady Children's Institute for Genomic Medicine Announce its First Research Collaboration for Whole - GlobeNewswire - June 24th, 2021
- Despite the challenges of COVID-19, Yale-PCCSM section members continued their work on scientific papers - Yale School of Medicine - June 24th, 2021
- Veritas Intercontinental: Genetics makes it possible to identify cardiovascular genetic risk and prevent cardiac accidents such as those that have... - June 24th, 2021
- New Research Uncovers How Cancers with Common Gene Mutation Develop Resistance to Targeted Drugs - Newswise - June 24th, 2021
- Celebrate the Third Annual Medical Genetics Awareness Week April 13-16, 2021 - PRNewswire - February 14th, 2021
- How will WNY fare in the race between vaccines and coronavirus variants? - Buffalo News - February 14th, 2021
- Myriad Genetics to Participate in Multiple Upcoming Health and Technology Conferences - GlobeNewswire - February 14th, 2021
- ASCO GU 2021: The Landscape of Genetic Alterations Using ctDNA-based Comprehensive Genomic Profiling in Pat... - UroToday - February 14th, 2021
- The Human Genome and the Making of a Skeptical Biologist - Scientific American - February 14th, 2021
- Breast Cancer Gene Mutations Found in 30% of All Women - Medscape - February 1st, 2021
- Mysterious untreatable fevers once devastated whole families. This doctor discovered what caused them - CNN - February 1st, 2021
- CCMB team identifies variants of genes that metabolise drugs - BusinessLine - February 1st, 2021
- NeuBase Therapeutics Announces Acquisition of Gene Modulating Technology from Vera Therapeutics - GlobeNewswire - February 1st, 2021
- Copy number variations linked to autism have diverse but overlapping effects - Spectrum - February 1st, 2021
- Genomes, Maps, And How They Affect You - IFLScience - February 1st, 2021
- SMART Study Finds 22q11.2 Microdeletion Prevalence Much Higher than Expected - PRNewswire - February 1st, 2021
- Are Phages Overlooked Mediators of Health and Disease? - The Scientist - February 1st, 2021
- When Your Chance for a Covid Shot Comes, Dont Worry About the Numbers - Kaiser Health News - February 1st, 2021
- Global CRISPR Gene Editing Market: Focus on Products, Applications, End Users, Country Data (16 Countries), and Competitive Landscape - Analysis and... - February 1st, 2021
- The First Targeted Therapy For Lung Cancer Patients With The KRAS Gene MutationExtraordinary Results With Sotorasib - SurvivorNet - February 1st, 2021
- Genetic Testing: MedlinePlus - January 29th, 2021
- 21 Common Genetic Disorders: Types, Symptoms, Causes ... - January 29th, 2021
- Genetic Counseling Online Course - School of Medicine ... - January 29th, 2021